Lincoln Pharmaceuticals Share Price | Lincoln Pharmaceuticals Stock Screener
LINCOLN
Pharmaceuticals
Share Price NSE
₹758.15
▲
10.70 (1.43%)
Share Price BSE
₹758.35
▲
13.10 (1.76%)
As of May 27, 2026, the Lincoln Pharmaceuticals share price (NSE: LINCOLN) is ₹758.15 on NSE and ₹758.35 on BSE, up 1.43% from the previous close, with shares trading between ₹738.30 and ₹770.00, and a 52-week range of ₹444.20–₹758.15.
Check Lincoln Pharmaceuticals yearly highs lows for the annual price range and momentum.
Use the Lincoln Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Lincoln Pharmaceuticals Market Cap
₹1,440.44 Cr.
LINCOLN P/E Ratio (TTM)
16.73
Lincoln Pharmaceuticals P/B Ratio
2.05
EPS (TTM)
₹41.11
Dividend Yield
0.25%
Debt to Equity
-
LINCOLN 52 Week High
₹758.15
Lincoln Pharmaceuticals 52 Week Low
₹444.20
Operating Margin
16.00%
Profit Margin
7.45%
LINCOLN Revenue (TTM)
₹161.00
EBITDA
₹20.00
Net Income
₹12.00
Total Assets
₹797.00
Total Equity
₹672.00
Lincoln Pharmaceuticals Share Price Chart
Screen Lincoln Pharmaceuticals share price with an interactive chart. Analyse LINCOLN price trends and volatility across different timeframes.
Lincoln Pharmaceuticals Company Profile - Fundamental Screener
Screen Lincoln Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for LINCOLN shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE405C01035
Lincoln Pharmaceuticals Balance Sheet Screener
Screen LINCOLN balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 797 | 700 | 587 | 534 | 452 | 389 | 366 | 347 | 305 | 275 |
| Current Assets | 500 | 447 | 367 | 353 | 309 | 248 | 224 | 218 | 181 | 147 |
| Fixed Assets | 182 | 179 | 151 | 132 | 111 | 123 | 121 | 117 | 103 | 99 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 19 | 15 | 13 | 11 | 10 | 10 | 11 | 18 | 22 | 34 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 672 | 593 | 503 | 433 | 366 | 314 | 270 | 225 | 193 | 141 |
| Share Capital | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 16 |
| Reserves & Surplus | 652 | 573 | 482 | 413 | 346 | 293 | 249 | 204 | 172 | 117 |
Lincoln Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Lincoln Pharmaceuticals income statement and profit fundamentals.
Analyze LINCOLN quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Lincoln Pharmaceuticals share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 161 | 169 | 171 | 182 | 150 | 158 | 171 | 156 | 116 | 143 | 165 | 158 | 105 | 130 | 146 |
| Expenses | 142 | 130 | 138 | 143 | 124 | 125 | 133 | 123 | 96 | 115 | 125 | 117 | 85 | 107 | 112 |
| EBITDA | 20 | 39 | 33 | 39 | 25 | 33 | 38 | 33 | 21 | 28 | 40 | 41 | 19 | 23 | 35 |
| Operating Profit % | 16.00% | 15.00% | 16.00% | 14.00% | 13.00% | 15.00% | 18.00% | 16.00% | 15.00% | 15.00% | 20.00% | 20.00% | 17.00% | 14.00% | 21.00% |
| Depreciation | 3 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 2 | 2 | 2 |
| Interest | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Profit Before Tax | 16 | 35 | 29 | 35 | 22 | 30 | 35 | 29 | 17 | 26 | 37 | 38 | 17 | 21 | 32 |
| Tax | 5 | 8 | 9 | 6 | 4 | 6 | 8 | 8 | 4 | 6 | 9 | 10 | 6 | 6 | 8 |
| Net Profit | 12 | 28 | 20 | 29 | 19 | 24 | 26 | 21 | 13 | 19 | 28 | 28 | 11 | 15 | 24 |
| EPS | 5.78 | 13.82 | 9.98 | 14.28 | 9.28 | 11.82 | 13.15 | 10.37 | 6.27 | 9.49 | 13.81 | 14.00 | 5.50 | 7.49 | 11.84 |
Lincoln Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen LINCOLN cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 93 | 63 | 39 | 76 | 69 | 75 | 53 | 27 | 25 | 45 |
| Investing Activities | -79 | -57 | -37 | -78 | -64 | -31 | -18 | -12 | -26 | -42 |
| Financing Activities | -6 | -5 | -5 | -3 | -6 | -38 | -36 | -11 | 0 | -3 |
| Net Cash Flow | 8 | 1 | -2 | -5 | -1 | 7 | -1 | 4 | 0 | 0 |
Lincoln Pharmaceuticals Shareholding Pattern Screener
See Lincoln Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings.
Check Lincoln Pharmaceuticals promoter holding and ownership changes for LINCOLN on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% | 49.53% | 49.78% | 49.78% |
| FII Holding | 5.19% | 5.00% | 5.14% | 4.72% | 4.70% | 3.93% | 3.95% | 5.19% |
| DII Holding | 1.09% | 0.01% | 0.01% | 0.01% | 0.01% | 0.05% | 0.04% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 34.70% | 36.64% | 36.27% | 36.26% | 36.29% | 37.36% | 37.10% | 36.14% |
| Other Holding | 9.24% | 8.59% | 8.81% | 9.23% | 9.23% | 9.13% | 9.14% | 8.89% |
| Shareholder Count | 28,303 | 31,867 | 31,784 | 32,370 | 31,026 | 31,375 | 29,967 | 31,330 |
Lincoln Pharmaceuticals Share Dividend Screener - Share Yield Analysis
Check Lincoln Pharmaceuticals dividend history with payout and yield data.
View Lincoln Pharmaceuticals dividend details including ex-dates and amounts for LINCOLN stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹1.80 | 0.32% |
| 2024-March | ₹1.80 | 0.33% |
| 2023-March | ₹1.50 | 0.26% |
| 2022-March | ₹1.50 | 0.44% |
| 2021-March | ₹1.50 | 0.48% |
| 2020-March | ₹1.50 | 0.67% |
| 2019-March | ₹1.50 | 1.16% |
| 2018-March | ₹1.50 | 0.71% |
| 2017-March | ₹1.20 | 0.56% |
Lincoln Pharmaceuticals Stock Index Membership
See which indices include Lincoln Pharmaceuticals stock.
Check LINCOLN index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE INDEX BSE HC
BSE INDEX SMLCAP
Lincoln Pharmaceuticals Market Events Screener - Corporate Actions
Get Lincoln Pharmaceuticals corporate actions including splits, bonuses, and buybacks.
Check Lincoln Pharmaceuticals stock events that may affect LINCOLN share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -2.11% | ||
| Dividend | ₹ 1.50 /share | 19.82% | ||
| Dividend | ₹ 1.50 /share | -4.87% | ||
| Dividend | ₹ 1.50 /share | 16.16% | ||
| Dividend | ₹ 1.80 /share | 28.22% | ||
| Annual General Meeting | NA | -4.13% | ||
| Dividend | ₹ 1.80 /share | -7.23% | ||
| 2026-05-28 | 2026-05-28 | Quarterly Result Announcement | NA | 13.81% |
| 2026-02-12 | 2026-02-12 | Quarterly Result Announcement | NA | 10.57% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | 0.52% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | -2.07% |
| 2025-05-22 | 2025-05-22 | Quarterly Result Announcement | NA | 2.21% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | -4.25% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -5.02% |
Lincoln Pharmaceuticals Competitors Screener - Peer Comparison
Screen LINCOLN competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 441,622 | 40.42 | 58,220 | 6.38% | 11,565 | 54.03 |
| Divis Laboratories | 179,364 | 73.73 | 10,560 | 8.73% | 2,520 | 57.30 |
| Torrent Pharmaceuticals | 154,758 | 66.80 | 13,753 | 19.18% | 2,028 | 66.36 |
| Cipla | 114,212 | 29.26 | 27,712 | -2.46% | 3,783 | 64.19 |
| Dr Reddys Laboratories | 111,124 | 26.24 | 33,593 | -0.44% | 3,998 | 57.44 |
| Zydus Life Science | 107,964 | 20.40 | 26,720 | 13.65% | 5,242 | 73.90 |
| Lupin | 104,535 | 19.46 | 27,488 | 19.98% | 5,345 | 48.15 |
| Mankind Pharma | 101,447 | 52.84 | 14,278 | 12.03% | 1,750 | 59.66 |
| Aurobindo Pharma | 84,483 | 24.29 | 33,385 | 3.21% | 3,376 | 51.11 |
| Laurus Labs | 73,221 | 81.46 | 6,813 | 21.03% | 884 | 78.36 |
Lincoln Pharmaceuticals Company Announcements - News Screener
Screen LINCOLN latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-05-22 | Corporate Action-Board to consider Dividend | - |
| 2026-05-22 | Board Meeting Intimation for Consideration Of Audited (Standalone & Consolidated) Financial Results Of The Company For The Quarter And Year Ended On March 31 2026. | - |
| 2026-05-12 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-08 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-05 | Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 | - |
| 2026-04-16 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-04-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-25 | Closure of Trading Window | - |
| 2026-02-23 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-02-18 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-02-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-12 | UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31.12.2025 | - |
| 2026-02-12 | Board Meeting Outcome for OUTCOME OF BOARD MEETING | - |
| 2026-02-04 | Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Third Quarter And Nine Months Ended 31St December 2025. | - |
| 2026-01-10 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-01-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-12-24 | Closure of Trading Window | - |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2025-11-13 | UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30.09.2025 | - |